« Return to News | R&D Trends

Access launches initiative to fund early-stage therapeutic companies

Monday, December 19, 2011 02:56 PM

Access Industries has established Access BridgeGap Ventures, a new life sciences venture investment initiative to fund early-stage companies in the therapeutics space. Access BridgeGap will fund early-stage startups and also create de-novo spinoffs around potential high-impact technologies, many of which are still in academic labs.

Funding activities will focus on scientists, entrepreneurs, and companies that are developing novel and clinically relevant therapeutic approaches and platforms that can become must-have solutions for patients, physicians, and payers. The group is led by Daniel Behr, MBA, and Ben Bronstein, MD, both entrepreneurs and technology developers.

According to Daniel Behr, founder and senior vice president, "With Access' support we have the resources and flexibility to span all investment stages and build fully independent companies, either alone or with other investors.  Access BridgeGap expects to fund 3-5 companies per year and to deploy $75M over the first few years."

Access BridgeGap Ventures, based in Cambridge, MA, is actively seeking opportunities in human therapeutics: pharmaceuticals, biopharmaceuticals and therapeutic devices.  

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.